Total Payments
$131,811
2024 Payments
$97,958
Companies
29
Transactions
194
Medicare Patients
13,037
Medicare Billing
$3.8M
Payment Breakdown by Category
Consulting$78,494 (59.6%)
Other$36,433 (27.6%)
Travel$9,923 (7.5%)
Food & Beverage$5,761 (4.4%)
Research$1,189 (0.9%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $78,494 | 25 | 59.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,433 | 12 | 27.6% |
| Travel and Lodging | $9,923 | 32 | 7.5% |
| Food and Beverage | $5,761 | 123 | 4.4% |
| Unspecified | $1,189 | 1 | 0.9% |
| Education | $11.92 | 1 | 0.0% |
Payments by Type
General
$130,622
193 transactions
Research
$1,189
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25,940 | 16 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $22,701 | 20 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $21,310 | 10 | $0 (2024) |
| GlaxoSmithKline, LLC. | $19,071 | 15 | $0 (2024) |
| Amgen Inc. | $14,367 | 39 | $0 (2024) |
| ABBVIE INC. | $13,171 | 27 | $0 (2024) |
| Genentech, Inc. | $5,387 | 4 | $0 (2023) |
| TAIHO ONCOLOGY, INC. | $3,557 | 7 | $0 (2024) |
| GENZYME CORPORATION | $2,025 | 2 | $0 (2024) |
| Kite Pharma, Inc. | $1,610 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $97,958 | 118 | E.R. Squibb & Sons, L.L.C. ($25,913) |
| 2023 | $19,279 | 39 | Novartis Pharmaceuticals Corporation ($8,581) |
| 2022 | $7,174 | 25 | ABBVIE INC. ($4,740) |
| 2021 | $7,049 | 8 | Novartis Pharmaceuticals Corporation ($4,950) |
| 2020 | $124.99 | 1 | Amgen Inc. ($124.99) |
| 2019 | $151.00 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($124.73) |
| 2017 | $74.50 | 1 | Incyte Corporation ($74.50) |
All Payment Transactions
194 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,820.00 | General |
| 12/09/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Consulting Fee | Cash or cash equivalent | $2,537.50 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $58.35 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2024 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Food and Beverage | In-kind items and services | $267.31 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $31.35 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $8.35 | General |
| Category: Oncology | ||||||
| 11/22/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $9.80 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $34.97 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: Oncology | ||||||
| 11/08/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,450.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Amgen Inc. | Blincyto (Biological) | Travel and Lodging | Cash or cash equivalent | $59.10 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Oncology | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,566.00 | General |
| Category: Hematology | ||||||
| 10/18/2024 | Amgen Inc. | Blincyto (Biological) | Travel and Lodging | In-kind items and services | $234.98 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 10/15/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $81.32 | General |
| Category: Hematology | ||||||
| 10/15/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $68.46 | General |
| Category: Hematology | ||||||
| 10/15/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $37.00 | General |
| Category: Hematology | ||||||
| 10/14/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $32.79 | General |
| Category: Oncology | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $950.31 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $1,189 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 78 | 3,967 | 162,170 | $8.1M | $1.8M |
| 2022 | 73 | 3,871 | 135,733 | $5.3M | $870,580 |
| 2021 | 71 | 3,271 | 104,348 | $4.9M | $1.0M |
| 2020 | 51 | 1,928 | 26,952 | $920,357 | $200,931 |
Total Patients
13,037
Total Services
429,203
Medicare Billing
$3.8M
Procedure Codes
273
All Medicare Procedures & Services
273 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0896 | Injection, luspatercept-aamt, 0.25 mg | Office | 2023 | 11 | 21,400 | $2.2M | $653,178 | 29.9% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 18 | 12,400 | $1.8M | $537,035 | 29.5% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 30 | 35,085 | $736,785 | $83,016 | 11.3% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 11 | 2,460 | $617,920 | $81,993 | 13.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 248 | 532 | $119,168 | $50,472 | 42.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 122 | 363 | $109,263 | $48,259 | 44.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 113 | 375 | $257,250 | $39,546 | 15.4% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 46 | 1,358 | $237,650 | $26,407 | 11.1% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 17 | 312 | $274,248 | $25,275 | 9.2% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 12 | 3,340 | $100,200 | $20,581 | 20.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 304 | 2,098 | $73,430 | $15,905 | 21.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 303 | 1,882 | $35,758 | $15,761 | 44.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 241 | 1,334 | $82,708 | $13,720 | 16.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 120 | 247 | $75,088 | $12,358 | 16.5% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 41 | 106 | $26,606 | $8,204 | 30.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 12 | 57 | $224,466 | $7,524 | 3.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 124 | 610 | $56,730 | $6,681 | 11.8% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 21 | 16,320 | $97,920 | $6,574 | 6.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 46 | 46 | $15,778 | $5,566 | 35.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 36 | 96 | $32,064 | $5,092 | 15.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 16 | 84 | $17,220 | $4,808 | 27.9% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 67 | 177 | $44,073 | $4,620 | 10.5% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 31 | 33 | $17,259 | $4,614 | 26.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 65 | 196 | $29,792 | $4,460 | 15.0% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 15 | 32 | $31,552 | $4,192 | 13.3% |
About Dr. Christopher Benton, M.D
Dr. Christopher Benton, M.D is a Internal Medicine healthcare provider based in Englewood, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/20/2009. The National Provider Identifier (NPI) number assigned to this provider is 1255667655.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Benton, M.D has received a total of $131,811 in payments from pharmaceutical and medical device companies, with $97,958 received in 2024. These payments were reported across 194 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($78,494).
As a Medicare-enrolled provider, Benton has provided services to 13,037 Medicare beneficiaries, totaling 429,203 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 273 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Hematology & Oncology
- Location Englewood, CO
- Active Since 10/20/2009
- Last Updated 09/06/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1255667655
Products in Payments
- OJJAARA (Drug) $14,096
- REBLOZYL (Biological) $13,921
- Blincyto (Biological) $13,409
- VENCLEXTA (Drug) $13,146
- ULTOMIRIS (Biological) $8,486
- SCEMBLIX (Drug) $8,008
- Venclexta (Biological) $5,406
- INQOVI (Drug) $3,557
- Fabhalta (Drug) $2,363
- Tecartus (Drug) $1,610
- Kyprolis (Drug) $202.55
- Vanflyta (Drug) $128.53
- UKONIQ (Drug) $91.96
- Zoladex (Drug) $91.66
- DARZALEX (Biological) $66.81
- Vyloy (Drug) $66.32
- Xospata (Drug) $52.56
- PADCEV (Biological) $49.09
- SARCLISA (Biological) $47.69
- CABOMETYX (Drug) $39.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Englewood
Ian Kaminsky, M.d, M.D
Internal Medicine — Payments: $272,884
Internal Medicine $272,884
Aron Schwarcz, Md, MD
Internal Medicine — Payments: $48,520
Internal Medicine $48,520
Mr. Saqer Alkharabsheh, M.d, M.D
Internal Medicine — Payments: $48,061
Internal Medicine $48,061
Dr. Yonatan Bitton-Faiwiszewski, Md, MD
Internal Medicine — Payments: $32,877
Internal Medicine $32,877
Dr. Srikant Kondapaneni, Md, MD
Internal Medicine — Payments: $22,159
Internal Medicine $22,159
Saurabh Kapoor, Md, MD
Internal Medicine — Payments: $19,941
Internal Medicine $19,941